Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Feb 26;4:PO.19.00237. doi: 10.1200/PO.19.00237

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by American Society of Clinical Oncology

PMC Copyright notice

FIG 2. — Disease-free survival (DFS) in patients with KRAS exon 2 wild-type deficient DNA mismatch repair (dMMR)/microsatellite instability (MSI) stage III colon cancer treated with (A) FOLFOX (leucovorin, fluorouracil, and oxaliplatin) or (B) FOLFOX plus cetuximab according to dMMR mechanism (familial v sporadic origin) and in (C) familial and (D) sporadic dMMR/MSI cases according to treatment arm (FOLFOX v FOLFOX + cetuximab). Multivariable Cox models adjusted for age, sex, tumor grade, Eastern Cooperative Oncology Group performance status, pT/pN stage, and primary tumor location. HR, hazard ratio.